Neurological Surgery 脳神経外科49巻3号

2021年05月発行

特集 グリオーマ—現在の常識と近未来のスタンダード Ⅳグリオーマ治療法update

—▼TOPICS—グリオーマの遺伝子治療，ウイルス療法

著者： 黒住和彦¹ 小泉慎一郎¹ 大谷理浩²

所属機関： ¹浜松医科大学医学部脳神経外科 ²岡山大学大学院医歯薬学総合研究科脳神経外科

ページ範囲：P.608 - P.616

Point
・遺伝子治療は，腫瘍治療を目的として遺伝子または遺伝子を導入した細胞を人の体内に投与することである．
・ウイルス療法は，腫瘍特異的に腫瘍溶解性ウイルスが増殖し腫瘍を破壊する治療である．
・遺伝子治療，ウイルス療法も，さまざまな臨床試験が行われており，最近では認可される予定のものもある．さまざまな角度から検討と改良が加えられ，ますます発展していく．

参考文献

1）Okura H, et al：Gene therapy for malignant glioma. Mol Cell Ther 2：21, 2014

2）Caffery B, et al：Vectors for glioblastoma gene therapy：viral ＆ non-viral delivery strategies. Nanomaterials（Basel）9：105, 2019

3）Vecil GG, Lang FF：Clinical trials of adenoviruses in brain tumors：a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65：237-246, 2003

4）Watanabe M, et al：Adenovirus-mediated REIC/Dkk-3 gene therapy：development of an autologous cancer vaccination therapy（Review）. Oncol Lett 7：595-601, 2014

5）Oka T, et al：A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy. Sci Rep 6：33319, 2016

6）Shimazu Y, et al：Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Gene Ther 22：146-154, 2015

7）Car BD, et al：The toxicology of interleukin-12：a review. Toxicol Pathol 27：58-63, 1999

）gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther 25：106-116, 2018

9）Yamasaki T, et al：Genetically engineered multilineage-differentiating stress-enduring cells as cellular vehicles against malignant gliomas. Mol Ther Oncolytics 6：45-56, 2017

10）Ichikawa T, et al：In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 7：74-82, 2000

11）Kurozumi K, et al：Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol 66：117-127, 2004

12）Watanabe R, Takase-Yoden S：Gene expression of neurotropic retrovirus in the CNS. Prog Brain Res 105：255-262, 1995

13）Peltékian E, et al：Neurotropism and retrograde axonal transport of a canine adenoviral vector：a tool for targeting key structures undergoing neurodegenerative processes. Mol Ther 5：25-32, 2002

14）Braun E, et al：Neurotropism of herpes simplex virus type 1 in brain organ cultures. J Gen Virol 87（Pt 10）：2827-2837, 2006

15）O'Duibhir E, et al：Accelerating glioblastoma drug discovery：convergence of patient-derived models, genome editing and phenotypic screening. Mol Cell Neurosci 80：198-207, 2017

16）Matsumoto Y, et al：Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma. Acta Neuropathol Commun 8：42, 2020

17）Shimizu T, et al：δ-catenin promotes bevacizumab-induced glioma invasion. Mol Cancer Ther 18：812-822, 2019

18）Otani Y, et al：Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. Oncogene 37：777-786, 2018

19）Shimizu T, et al：Adhesion molecules and the extracellular matrix as drug targets for glioma. Brain Tumor Pathol 33：97-106, 2016

20）Onishi M, et al：Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma. Brain Tumor Pathol 32：184-194, 2015

21）Maruo T, et al：Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology 33：264-275, 2013

22）Inoue S, et al：Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg 78：670-682, 2012

23）Li S, et al：Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncology 69：503-508, 2005

24）難波宏樹：間葉系幹細胞を利用したグリオーマの治療戦略．Brain Nerve 62：1075-1082, 2010

25）Kosaka H, et al：Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer Gene Ther 19：572-578, 2012

26）Nakamura K, et al：Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11：1155-1164, 2004

27）Li S, et al：Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther 12：600-607, 2005

28）Li S, et al：Bystander effect in glioma suicide gene therapy using bone marrow stromal cells. Stem Cell Res 9：270-276, 2012

29）Amano S, et al：Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol 35：1265-1270, 2009

30）Koizumi S, et al：Migration of mouse-induced pluripotent stem cells to glioma-conditioned medium is mediated by tumor-associated specific growth factors. Oncol Lett 2：283-288, 2011

31）Yamazoe T, et al：Potent tumor tropism of induced pluripotent stem cells and induced pluripotent stem cell-derived neural stem cells in the mouse intracerebral glioma model. Int J Oncol 46：147-152, 2015

32）Li L, et al：Chimeric antigen receptor T-cell therapy in glioblastoma：current and future. Front Immunol 11：594271, 2020

33）Bressy C, et al：Combining oncolytic virotherapy with p53 tumor suppressor gene therapy. Mol Ther Oncolytics 5：20-40, 2017

34）Varghese S, Rabkin SD：Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9：967-978, 2002

35）Piao Y, et al：Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16：256-265, 2009

36）Mineta T, et al：Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1：938-943, 1995

37）Todo T, et al：Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 98：6396-6401, 2001

38）Kambara H, et al：An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65：2832-2839, 2005

39）Kurozumi K, et al：Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99：1768-1781, 2007

40）Kurozumi K, et al：Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99：1768-1781, 2007

41）Kurozumi K, et al：Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16：1382-1391, 2008

42）Fujii K, et al：The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 20：437-444, 2013

43）Hardcastle J, et al：Enhanced antitumor efficacy of vasculostatin（Vstat120）expressing oncolytic HSV-1. Mol Ther 18：285-294, 2010

44）Tomita Y, et al：Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways. Mol Cancer Ther 18：1418-1429, 2019

45）Otani Y, et al：Oncolytic HSV-infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition. Clin Cancer Res 26：2381-2392, 2020

46）Russell L, et al：PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nat Commun 9：5006, 2018

47）Mitchell LA, et al：PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget 10：2252-2269, 2019

48）Tamura R, et al：Recent progress in the research of suicide gene therapy for malignant glioma. Neurosurg Rev 44：29-49, 2021

49）Ram Z, et al：Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3：1354-1361, 1997

50）Tamura R, Toda M：Historic overview of genetic engineering technologies for human gene therapy. Neurol Med Chir（Tokyo）60：483-491, 2020

51）Mozhei O, et al：Viral vectors as gene therapy agents for treatment of glioblastoma. Cancers（Basel）12：3724, 2020

52）Cloughesy TF, et al：Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med 8：341ra75, 2016

53）Cloughesy TF, et al：Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511＋ Toca FC. Neuro Oncol 20：1383-1392, 2018

54）Kurozumi K, et al：Study protocol of a Phase Ⅰ/Ⅱa clinical trial of Ad-SGE-REIC for treatment of recurrent malignant glioma. Future Oncol 16：151-159, 2020

55）Chiocca EA, et al：Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma：results of a phase 1 trial. Sci Transl Med 11：eaaw5680, 2019

56）田中　実，藤堂具紀：ウイルス療法．日本臨牀 74（増刊号 7）：780-784, 2016